Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme sees Ceredase/Cerezyme sales of $250 mil. in 1996; plant approval will allow more growth.

Executive Summary

GENZYME CEREZYME MANUFACTURING FACILITY WILL ALLOW GROWTH BEYOND $250 MIL. in sales for the company's Ceredase/ Cerezyme Gaucher's disease treatment products, Genzyme CEO Henri Termeer told the Alex. Brown conference in Baltimore. Genzyme expects sales of the alglucerase products, predominantly from placenta-derived Ceredase, to reach $250 mil. this year, Termeer said. The firm's Boston manufacturing facility for recombinant Cerezyme is "in the final phases of review by FDA," Termeer added.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel